BEIJING, Aug. 03, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that orelabrutinib, in combination with mesutoclax (ICP-248), has been granted Breakthrough Therapy…
BEIJING, July 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) met the primary endpo…
BEIJING, July 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma HKEX:09969; SSE:688428, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that registrational phase III clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor sofici…
